NCT01591889已完成1 期
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- bioequivalence determined by statistical comparison Cmax
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Tinidazole 500 mg Tablet under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to tinidazole or any comparable or similar product.
研究组 & 干预措施
tindamax
Active Comparator
500 mg tablet
干预措施: Tinidazole (Drug)
tinidazole
Active Comparator
500 mg tablet
干预措施: Tinidazole (Drug)
结局指标
主要结局
bioequivalence determined by statistical comparison Cmax
时间窗: 8 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting ConditionsIntermittent ClaudicationNCT00602407Roxane Laboratories36
已完成
不适用
Bioequivalency Study of Torsemide Tablets Under Fed ConditionsEdemaNCT00602615Roxane Laboratories28
已完成
不适用
Bioequivalency Study of Torsemide Tablets Under Fasting ConditionsEdemaNCT00602303Roxane Laboratories28
已完成
不适用
Bioequivalency Study of Zidovudine Under Fasting ConditionsHIV InfectionsNCT00602550Roxane Laboratories52
已完成
不适用
Bioequivalency Study of Zidovudine Under Fed ConditionsHIV InfectionsNCT00601562Roxane Laboratories52